Vijaya Raj Bhatt, MBBS, MS, discusses background and findings from a multicenter, phase 2 study of ruxolitinib for the treatment of patients with steroid refractory sclerotic chronic graft-versus-host disease.
Vijaya Raj Bhatt, MBBS, MS
Advertisement
Vijaya Raj Bhatt, MBBS, MS, is an associate professor in the Division of Oncology and Hematology and medical director of the Leukemia Program at the University of Nebraska Medical Center.
Articles by Vijaya Raj Bhatt, MBBS, MS
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
JANX007 Shows Promising Efficacy, Safety in Phase 1 Trial Update
4
LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors
5
